![jmp data analysis jmp data analysis](https://mma.prnewswire.com/media/1011082/SAS_JMP_Pro_15.jpg)
Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, but are not limited to, those regarding: the company's estimate of the period in which it expects to have cash to fund its operations the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells and the company's business strategies, plans and prospects. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections.
![jmp data analysis jmp data analysis](https://www.csensems.com/wp-content/uploads/2021/06/CSense-Data-Analysis-using-JMP.png)
Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.įor more information, visit and follow us on Twitter at. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.Ĭue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient.
#JMP DATA ANALYSIS SERIES#
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. EDTĪ live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company's website at The webcast will be archived for 30 days. Date and Time: Thursday, June 16 at 1:00 p.m.–1:25 p.m.